RxDoctor Payments Data

Kimberly Stack

Psychiatric/Mental Health · Clifton Park, NYNPI 1366413536

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (58.0%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 45.6% of the total. Reporting peaked in 2021 at $4,263 and has fallen 72.3% since, to $1,179 in 2025. Among psychiatric/mental health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,723in general payments, 2019–2025

Across 347 payments — averaging $30.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$5K
  • AbbVie$2K
  • Johnson & Johnson$539
  • Teva Pharmaceuticals USA, Inc.$536
  • Otsuka America Pharmaceutical, Inc.$411
  • Axsome Therapeutics, Inc.$403
  • plus $2K from 26 others

What the payments were for

  • Consulting fees$1,31312%
  • Speaking & faculty fees$3,18830%
  • Food & beverage$6,22358%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,723 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide15$10,049
Desvenlafaxine Succinate ErDesvenlafaxine Succinate32$1,565
Duloxetine Hcl26$458
Venlafaxine Hcl ErVenlafaxine Hcl18$447
Mirtazapine18$360
Alprazolam22$290
Buspirone Hcl16$242
Alprazolam ErAlprazolam11$217
Trazodone Hcl18$161
Lamotrigine12$145
Clonazepam12$90
Fluoxetine Hcl18$49
Sertraline Hcl21$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$163$10,04915 claims
Almatica Pharma LLCSertraline Hcl$16$4221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Clifton Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →